Design, synthesis and biological evaluation of pyridine-phenylpiperazines: A novel series of potent and selective α(1a)-adrenergic receptor antagonist

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 9, 2000, Pages 2263-2275

  Kuo, Gee Hong ^a   Prouty, Catherine ^a   Murray, William V ^a   Pulito, Virginia ^a   Jolliffe, Linda ^a   Cheung, Peter ^a   Varga, Sally ^a   Evangelisto, Mary ^a   Shaw, Charles ^b  

^a Drug Discovery Raritan   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; N [2 HYDROXY 3 [4 [2 (1 METHYLETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 2 PHENOXY 2 PYRIDINECARBOXAMIDE; PIPERAZINE DERIVATIVE; RECEPTOR SUBTYPE; RWJ 37914; TAMSULOSIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG SYNTHESIS; ENANTIOMER; HUMAN; IN VITRO STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; PROSTATE; PROSTATE HYPERTROPHY; RAT; RECEPTOR BINDING; SMOOTH MUSCLE CONTRACTILITY; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY; URETHRA PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AORTA; BINDING, COMPETITIVE; BLOOD PRESSURE; COMBINATORIAL CHEMISTRY TECHNIQUES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MALE; MODELS, ANIMAL; MUSCLE CONTRACTION; PIPERAZINES; PROSTATE; PROTEIN BINDING; PYRIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, ADRENERGIC, ALPHA-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; VASOCONSTRICTOR AGENTS;

CANIS FAMILIARIS;

EID: 0033869072     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00151-6     Document Type: Article

References (55)

1. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R. Jr., Trendelenburg U. Pharmacol. Rev. 46:1994;121.
2. Hieble J.P., Bylund D.B., Clarke D.E., Eikenburg D.C., Langer S.Z., Lefkowitz R.J., Minneman K.P., Ruffolo R.R. Pharmacol. Rev. 47:1995;267.
3. Muramatsu I., Ohmura T., Kigoshi S., Hashimoto S., Oshita M. Br. J. Pharmacol. 99:1990;197.
4. Forray C., Bard J.A., Wetzel J.M., Chiu G., Shapiro E., Tang R., Lepor H., Hartig P.R., Weinshank R.L., Branchek T.A., Gluchowski C. Mol. Pharmacol. 45:1994;703.
5. Marshall I., Burt R.P., Chapple C.R. Br. J. Pharmacol. 115:1995;781.
6. Burt R.P., Chapple C.R., Marshall I. Br. J. Pharmacol. 116:1995;2327.
7. Hatano A., Takahashi H., Tamaki M., Komeyama T., Koizumi T., Takeda M. Br. J. Pharmacol. 113:1994;723.
8. (a) Kenny, B. A.; Chalmers, D. H.; Philpott, P. C.; Naylor, A. M. Br. J. Pharmacol. 1995, 115, 981.
9. (b) Aboud, R.; Shafii, M.; Docherty, J. R. Br. J. Pharmacol. 1993, 109, 80.
10. Lepor H., Henry D., Laddu A.R. Prostate. 18:1991;345.
11. Holme J.B., Christensen M.M., Rasmussen P.C., Jacobsen F., Nielsen J., Norgaard J.P., Olesen S., Noev I., Wolf H., Husted S.E. Scand. J. Urol. Nephrol. 28:1994;77.
12. Lepor H. J. Androl. 12:1991;389.
13. (a) Kawabe, K.; Ueno, A.; Takimoto, Y.; Aso, Y.; Kato, H. J. Urol, 1990, 144, 908.
14. (b) Rabasseda, X.; Fitzpatrick, J. M. Drugs of Today, 1996, 32 (Suppl. C), 1.
15. (a) Djavan, B.; Marberger, M. Eur. Urol, 1999, 36, 1.
16. (b) Lowe, F. Prostate Cancer and Prostatic Diseases, 1999, 2, 110.
17. (c) Schulman, C. C.; Cortvriend, J.; Jonas, U.; Lock, T. M. T. W.; Vaage, S.; Speakman, M. J. Eur. Urol, 1996, 29, 145.
18. (d) Jardin, A.; Andersson, K. E.; Caine, M. Alpha-blockers in the treatment of BPH. In The Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Denis, L.; Griffiths, K.; Khoury, S.; Cockett, A. T. K.; McConnell, J.; Chatelain, C.; Murphy, G.; Yoshida, O. Health Publication Ltd: Plymouth: UK, 1998; p599.
19. TM Life Science Products (Boston, MA).
20. Testa R., Guarneri L., Taddei C., Poggesi E., Angelico P., Sartani A., Leonardi A., Gofrit O.N., Meretyk S., Caine M. J. Pharmacol. Exp. Ther. 277:1996;1237.
21. Shibata K., Foglar R., Horie K., Obika K., Sakamoto A., Ogawa S., Tsujimoto G. Mol. Pharmacol. 48:1995;250.
22. Wetzel J.M., Miao S.W., Forray C., Borden L.A., Branchek T.A., Gluchowski C. J. Med. Chem. 38:1995;1579.
23. Cui, W.; Nakanishi, H.; Wetzel, J. M.; Gluchowski, C. 210th ACS National Meeting, Chicago, IL, 20-24 August 1995, MEDI-045.
24. Hamaguchi N., True T.A., Saussy D.L., Jeffs P.W. Jr. Biochemistry. 35:1996;14312.
25. Two second-generation leads were identified. The SAR and biological evaluation of the other second-generation lead, phthalimide-phenylpiperazine, is reported in Kuo, G.-H.; Prouty, C.; Murray, W. V.; Pulito, V.; Jolliff, L.; Cheung, P.; Varga, S.; Evangelisto, M.; Wang, J. J. Med. Chem. 2000, 43, 2183.
26. Martin G.E., Elgin R.J. Jr., Mathiasen J.R., Davis C.B., Kesslick J.M., Baldy W.J., Shank R.P., DiStefano D.L., Fedde C.L., Scott M.K. J. Med. Chem. 32:1989;1052.
27. Holy A. Collect. Czech. Chem. Commun. 54:1989;446.
28. Juricova K., Smrckova S., Holy A. Collect. Czech. Chem. Commun. 60:1995;237.
29. Topliss J.G. J. Med. Chem. 15:1972;1006.
30. Topliss J.G. J. Med. Chem. 20:1977;463.
31. Trumpp-Kallmeyer S., Hoflack J., Bruinvels A., Hibert M. J. Med. Chem. 35:1992;3448.
32. (a) Leff, P. Trends Pharmacol. Sci. 1995, 16, 89.
33. (b) Ford, A. P. D. W.; Arredondo, N. F.; Blue, D. R.; Bonhaus, D. W.; Jasper, J.; Kava, M. S.; Lesnick, J.; Pfister, J. R.; Shieh, I. A.; Vimont, R. L.; Williams, T. J.; McNeal, J. E.; Stamey, T. A.; Clarke, D. E. Mol. Pharmacol. 1996, 49, 209.
34. McCutchan J.H., Pagano J.S. J. Natl. Cancer. Inst. 41:1968;351.
35. Luthman H., Magnusson G. Nucleic Acids Res. 11:1983;1295.
36. Cheng Y.-C., Prusoff W.H. Biochem. Pharmacol. 22:1973;3099.
37. Uhlen S., Porter A.C., Neubig R.R. J. Pharmacol. Exp. Ther. 271:1994;1558.
38. Connaughton S., Docherty R. Br. J. Pharmacol. 101:1990;285.
39. Grandy D.K., Marchionni M.A., Makam H., Stofko R.E., Alfano M., Frothingham L, Fischer J.B., Bruke-Howie K.J., Bunzow J.R., Seiver A.C., Civelli O. Proc. Natl. Acad. Sci. USA. 86:1989;9762.
40. Bunzow J.R., Van Tol H.H.M., Grandy D.K., Albert P., Salon J., Christie M., Machida C.A., Neve K.A., Civelli O. Nature. 336:1988;783.
41. Hayes G., Biden T.J., Selbie L.A., Shine J. Molec. Endocrin. 6:1992;920.
42. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Nature. 347:1990;146.
43. Sibley D.R., Monsma F.J. Trends in Pharmacol. Sci. 13:1992;60.
44. Van Tol H.H.M., Wu C.M., Guan H.C., O'Hara K., Bunzow J.R., Civelli O., Kennedy J., Seeman P., Niznik H.B., Jovanovic V. Nature. 358:1992;149.
45. Van Tol H.H.M., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Nature. 350:1991;610.
46. Martin G.R., Humphrey P.P.A. Neuropharm. 33:1994;261.
47. Shen Y., Monsma F.J. Jr., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. J. Biol. Chem. 268:1993;18200.
48. Roth B.L., Craigo S.C., Choudhary M.S., Uluer S., Monsma F.J. Jr., Shen Y., Meltzer H.Y., Sibley D.R. J. Pharmacol. Exp. Ther. 268:1994;1403.
49. Middlemiss D.N. Eur. J. Pharmacol. 101:1984;289.
50. Gould R.J., Murphy K.M.M., Snyder S.H. Proc. Natl. Acad. Sci. USA. 79:1982;3650.
51. Ehlert F.J., Roeske W.R., Itoga E., Yamamura H.I. Life Sci. 30:1982;2191.
52. Brown C.M., Mackinnon A.C., McGrath J.C., Spedding M., Kilpatrick A.T. Br. J. Pharmacol. 99:1990;803.
53. Michel M.C., Ernsberger P. Trends. Pharmacol. Sci. 13:1992;369.
54. Hill S.J., Emson P.C., Young J.M. J. Neurochem. 31:1978;997.
55. Dini S., Caselli G.F., Ferrari M.P., Giani R., Clavenna G. Agents and Actions. 33:1991;181.